The extended study of two additional cohorts of the NA-PHER2 trial showed in cohort B of HER2-amplified breast carcinomas that block of HER2 and cdk4/6 led to a rapid and major drop of Ki67 even without the use of estrogen receptor targeting in spite of estrogen receptor expression. The gene discussed is ERBB2; the disease is breast carcinoma.